PTC Therapeutics (PTCT)
NASDAQ:PTCT
Want to see PTCT full AI Analyst Report?
Top Page
PTC Therapeutics
(NASDAQ:PTCT)
Select Model
Select Model
Rating:62Neutral
Price Target:
$68.00
▼(-6.12% Downside)
Action:ReiteratedDate:04/30/26
The score is driven by a sharp improvement in profitability and free cash flow plus constructive 2026 guidance and strong Sephience launch execution, partially offset by elevated balance-sheet risk (negative equity) and weak technical momentum (price below key moving averages with bearish indicators). Valuation is supportive due to a low P/E, but durability of earnings and revenue growth remains a key swing factor.
Positive Factors
High Profitability
The company’s TTM margins are structurally strong, implying durable unit economics and pricing power in its marketed products. High gross and operating margins provide buffer to fund R&D and commercialization, improving resilience if revenue growth moderates over the next 2–6 months.
Negative Factors
Negative Equity
Negative shareholders’ equity weakens financial flexibility and complicates leverage assessments. Even with improved cash, a negative equity base raises vulnerability to earnings reversals, restricts strategic optionality, and could pressure funding costs if cash generation stalls.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability
The company’s TTM margins are structurally strong, implying durable unit economics and pricing power in its marketed products. High gross and operating margins provide buffer to fund R&D and commercialization, improving resilience if revenue growth moderates over the next 2–6 months.
Read all positive factors
PTC Therapeutics (PTCT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.40B
Dividend YieldN/A
Average Volume (3M)1.02M
Price to Earnings (P/E)8.8
Beta (1Y)1.10
Revenue Growth114.51%
EPS GrowthN/A
CountryUS
Employees939
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)8.79
Shares Outstanding82,911,780
10 Day Avg. Volume927,962
30 Day Avg. Volume1,016,765
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-29.43
Price to Sales (P/S)3.49
P/FCF Ratio8.60
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue2.84
Enterprise Value/Gross Profit3.12
Enterprise Value/Ebitda5.53
Forecast
1Y Price Target
$91.82Price Target Upside26.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$972.48M
PTC Therapeutics Business Overview & Revenue Model
Company Description
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various s...
How the Company Makes Money
PTC Therapeutics primarily generates revenue from (1) product sales of its marketed therapies, where revenue is recognized from net sales (gross sales less discounts, rebates, returns, and other allowances) in the territories where it commercializ...
PTC Therapeutics Key Performance Indicators (KPIs)
Any
Revenue by Product
Shows how much revenue each product generates, highlighting which products are driving growth and which may need strategic adjustments.
Shows how much revenue each product generates, highlighting which products are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyPTC Therapeutics Earnings Call Summary
Earnings Call Date:Feb 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call conveyed a strongly positive commercial and financial story driven by Sephience's rapid global approvals and impressive early launch metrics, revenue outperformance for 2025, a strengthened cash position (~$1.95B), disciplined OpEx, and clear R&D progress (notably votoplam Phase III alignment). Offsetting items include regulatory setbacks for vatiquinone requiring additional study, reduced future Evrysdi royalty exposure following a royalty sale, pressure on the DMD franchise from generics, and some near-term expense increases and geographic concentration of Sephience revenue. Overall, the positives (robust launch, revenue beat, cash runway, and advancing pipeline programs) materially outweigh the negatives, though several development and commercialization risks remain.Positive Updates
Successful Global Sephience Approvals and Launch
Sephience gained approvals in the U.S., EU, Japan and other countries in 2025 and launched globally with strong early uptake. Q4 2025 Sephience revenue was $92M (U.S. $81M, ex-U.S. $11M) and Sephience generated $111M worldwide since launch in 2025. As of Dec 31, 2025 there were 946 patients on commercial therapy and 1,134 patient start forms in the U.S.; >80% of U.S. PKU centers of excellence have prescribed Sephience.
Negative Updates
Vatiquinone CRL and Need for Additional Study
FDA issued a Complete Response Letter (CRL) for vatiquinone and indicated that additional study will be necessary to support NDA resubmission; FDA suggested an open-label single-arm study with a natural history comparator. This introduces development delay and regulatory uncertainty; a Type C meeting was held and a Q2 2026 meeting is planned to align on protocol.
Read all updates
Q4-2025 Updates
Positive
Negative
Successful Global Sephience Approvals and Launch
Sephience gained approvals in the U.S., EU, Japan and other countries in 2025 and launched globally with strong early uptake. Q4 2025 Sephience revenue was $92M (U.S. $81M, ex-U.S. $11M) and Sephience generated $111M worldwide since launch in 2025. As of Dec 31, 2025 there were 946 patients on commercial therapy and 1,134 patient start forms in the U.S.; >80% of U.S. PKU centers of excellence have prescribed Sephience.
Read all positive updates
Company Guidance
PTC guided 2026 product revenue of $700–$800 million (up 19%–36% YoY vs. 2025), with the majority from Sephience (guidance excludes Evrysdi royalty revenue after sale of the remaining royalty to Royalty Pharma — $240M upfront, up to $60M in milestones; PTC retains a $150M Roche milestone tied to $2.5B single‑year Evrysdi sales). They forecast non‑GAAP R&D plus SG&A of $680–$720M (excluding ~ $95M of noncash stock‑based comp) and said the company has the potential to reach cash‑flow breakeven in 2026. For context, Q4/2025 net product & royalty revenue was $263M and FY2025 totaled $831M (total product revenue $587M), with Sephience contributing $92M in Q4 and $111M since launch in 2025; Q4 DMD franchise revenue was $66M (Translarna $39M, Emflaza $27M); Evrysdi drove Q4 royalty of $79M and FY royalty of $244M. Non‑GAAP R&D+SG&A OpEx for 2025 was $728M (below prior guidance of $730–$760M), cash at year‑end was $1.95B (vs. $1.14B a year earlier), Sephience had 946 commercial patients worldwide (1,134 U.S. patient start forms) as of Dec 31, 2025, and the company expects commercial patients in 20–30 countries by year‑end 2026; gross‑to‑net is modeled at ~15%–25% (starting at the lower end).PTC Therapeutics Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
34
Negative
Cash Flow
73
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.73B | 806.78M | 937.82M | 698.80M | 538.59M |
| Gross Profit | 1.66B | 749.38M | 872.34M | 654.12M | 506.26M |
| EBITDA | 887.66M | -120.46M | -330.34M | -367.78M | -368.18M |
| Net Income | 682.64M | -363.30M | -626.60M | -559.02M | -523.90M |
Balance Sheet | |||||
| Total Assets | 2.91B | 1.71B | 1.90B | 1.71B | 1.94B |
| Cash, Cash Equivalents and Short-Term Investments | 1.95B | 1.14B | 876.74M | 410.70M | 773.38M |
| Total Debt | 492.28M | 2.47B | 2.23B | 1.46B | 1.27B |
| Total Liabilities | 3.12B | 2.80B | 2.71B | 2.05B | 1.94B |
| Stockholders Equity | -205.31M | -1.10B | -818.55M | -347.09M | 1.44M |
Cash Flow | |||||
| Free Cash Flow | 702.34M | -181.94M | -279.04M | -509.11M | -336.66M |
| Operating Cash Flow | 711.20M | -107.69M | -158.42M | -356.65M | -251.33M |
| Investing Cash Flow | -861.98M | 44.18M | -176.74M | 290.18M | 219.18M |
| Financing Cash Flow | 331.09M | 255.87M | 646.40M | 167.95M | 20.88M |
PTC Therapeutics Technical Analysis
Positive
72.43
Price Trends
68.47
Positive
72.67
Negative
65.51
Positive
Market Momentum
1.25
Negative
58.95
Neutral
79.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTCT, the sentiment is Positive. The current price of 72.43 is above the 20-day moving average (MA) of 68.84, above the 50-day MA of 68.47, and above the 200-day MA of 65.51, indicating a bullish trend. The MACD of 1.25 indicates Negative momentum. The RSI at 58.95 is Neutral, neither overbought nor oversold. The STOCH value of 79.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTCT.
PTC Therapeutics Risk Analysis
PTC Therapeutics disclosed 53 risk factors in its most recent earnings report. PTC Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PTC Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $5.40B | 8.85 | -362.44% | ― | 114.51% | ― | |
61 Neutral | $5.41B | 9.62 | 101.12% | ― | 87.32% | 1802.16% | |
56 Neutral | $8.22B | -8.19 | -25.88% | ― | ― | -47.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $4.98B | -8.11 | -31.53% | ― | -90.59% | -49.45% |
* Healthcare Sector Average
PTCT
PTC Therapeutics
65.15
24.50
60.27%
TGTX
TG Therapeutics
33.85
-3.83
-10.16%
CRSP
Crispr Therapeutics AG
51.63
14.01
37.24%
PCVX
Vaxcyte
56.93
22.65
66.07%
PTC Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
PTC Therapeutics Reports Positive 24-Month Votoplam Data
Positive
Apr 28, 2026
On April 28, 2026, PTC Therapeutics reported positive 24‑month interim data from the PIVOT‑HD long‑term extension study of votoplam in Huntington’s disease, showing a dose‑dependent slowing of disease progression in S...
Business Operations and StrategyExecutive/Board Changes
PTC Therapeutics Adds Veteran Banker to Board
Positive
Mar 25, 2026
On March 24, 2026, PTC Therapeutics appointed veteran biotechnology investment banker Jessica Chutter to its board of directors as a Class I director, with her term running until the 2026 annual shareholders’ meeting. Chutter, who recently r...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
PTC Therapeutics Tops 2025 Revenue Guidance, Boosts Cash
Positive
Feb 19, 2026
On Feb. 19, 2026, PTC Therapeutics reported that full-year 2025 product and royalty revenue reached $831 million, exceeding guidance, driven by the successful global launch of Sephience, which generated $111 million since its second-half 2025 debu...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
PTC Therapeutics Withdraws Translarna NDA After FDA Feedback
Negative
Feb 12, 2026
On February 12, 2026, PTC Therapeutics withdrew its New Drug Application resubmission for Translarna (ataluren), a protein restoration therapy for nonsense mutation Duchenne muscular dystrophy, after the U.S. Food and Drug Administration indicated...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.